GlassScriptPhysician profile
Lisa S Ball
NPI 1497802672
$7,368.44
in general payments reported to CMS, 2019-2025
24 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $955 · 2022: $1,622 · 2023: $1,721 · 2024: $1,700 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,437 · Education: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.93 |
| Education | $353.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.35 | 2021-2025 | |
| Janssen Biotech, INC. | $1,155.83 | 2021-2025 | Tremfya |
| Pfizer INC. | $959.88 | 2021-2025 | |
| Lilly USA, LLC | $554.11 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $475.89 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $420.11 | 2021-2025 | Dupixent |
| Amgen INC. | $320.43 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $295.89 | 2021-2025 | |
| Ucb, INC. | $292.18 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $222.26 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $211.69 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $191.78 | 2021-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $178.32 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $152.39 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $139.46 | 2022-2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $101.43 | 2022-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.58 | 2021 | |
| Sandoz INC. | $42.27 | 2024-2025 | Hyrimoz |
| Organon LLC | $40.22 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $38.38 | 2025 | Nuzyra |
| Vyne Pharmaceuticals INC. | $24.91 | 2021 | |
| Biofrontera INC. | $22.92 | 2021 | |
| Stryker Corporation | $19.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.